On November 18, 2013 Patrys reported that it has been granted a second Australian patent for clinical anti-cancer product PAT-SM6 (Press release Patrys, NOV 18, 2013, View Source [SID:1234500548]).
The Australian Patent Office has issued the official "Notice of Grant" on a key patent in the PAT-SM6 family; application number 2007355108 entitled "Novel glycosylated peptide target in neoplastic cells". It offers patent protection through to November 2027.
This is the second patent to be granted in Australia.
This patent is one of a series of patent applications that have been submitted to cover the PAT-SM6 product, target and mechanism of action. The claims in this patent cover the PAT-SM6 antibody and binding fragments and methods of use of the antibody and binding fragments for treatment of various cancers including multiple myeloma. In February 2012, Patrys was granted a patent by the US Patent Office that contains claims that cover the PAT-SM6 antibody which binds to apolipoprotein B containing low-density lipoprotein (LDL) and apolipoprotein B containing oxidised LDL which are part of the complex, multistep mechanism of action for the product. To date, seven patents in the PAT-SM6 family have been granted in various jurisdictions including Europe, Japan, the US and Australia.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!